Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 8/20 | 0.61 |
| ▸ | CA12 | O43570 | 2/20 | 0.59 |
| ▸ | CA1 | P00915 | 2/20 | 0.59 |
| ▸ | CA2 | P00918 | 2/20 | 0.59 |
| ▸ | CA7 | P43166 | 2/20 | 0.59 |
| ▸ | CA9 | Q16790 | 2/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.59 |
| ▸ | ESR1 | P03372 | 2/20 | 0.59 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | ALPI | P09923 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | ALPG | P10696 | 1/20 | 0.53 |
| ▸ | APEX1 | P27695 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10749473 | 0.87 | KMT2A (0.61) | NPC1RAB9AALDH1A1TDP1POLB | |
| SCHEMBL4686898 | 0.84 | LMNA (0.61) | NPC1RAB9AALDH1A1TDP1KDM4E | |
| SCHEMBL10596300 | 0.84 | KMT2A (0.65) | NPC1RAB9AALDH1A1TDP1POLB | |
| SCHEMBL6650021 | 0.84 | LMNA (0.61) | NPC1RAB9AALDH1A1TDP1KDM4E | |
| SCHEMBL10456907 | 0.84 | KMT2A (0.68) | NPC1RAB9AALDH1A1TDP1POLB | |
| SCHEMBL2437915 | 0.84 | L3MBTL1 (0.59) | NPC1ALDH1A1TDP1POLBGAA | |
| SCHEMBL8085697 | 0.84 | CA12 (0.61) | HSD17B3CA12CA1CA2CA7 | |
| SCHEMBL1375197 | 0.83 | MMP1 (0.59) | NPC1RAB9AALDH1A1L3MBTL1MAPT | |
| SCHEMBL12556748 | 0.83 | KMT2A (0.56) | NPC1RAB9AALDH1A1TDP1POLB | |
| SCHEMBL11824190 | 0.83 | KMT2A (0.56) | NPC1RAB9AALDH1A1TDP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2502918-B1 | Pyridazinone Derivatives | CEPHALON INC (US) | 2015-03-25 | — | — | EP | disclosed |
| EP-2502918-B1 | Pyridazinone Derivatives | CEPHALON INC (US) | 2015-03-25 | — | — | EP | disclosed |
| US-20140142088-A1 | PYRIDAZINONE DERIVATIVES | CEPHALON, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142088-A1 | PYRIDAZINONE DERIVATIVES | CEPHALON, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142088-A1 | PYRIDAZINONE DERIVATIVES | CEPHALON, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-8673916-B2 | Methods of treating disorders mediated by histamine H3 receptors using pyridazinone derivatives | CEPHALON, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673916-B2 | Methods of treating disorders mediated by histamine H3 receptors using pyridazinone derivatives | CEPHALON, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673916-B2 | Methods of treating disorders mediated by histamine H3 receptors using pyridazinone derivatives | CEPHALON, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8586588-B2 | Aryl pyridazinone derivatives and their use as H3 receptor ligands | CEPHALON, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-8586588-B2 | Aryl pyridazinone derivatives and their use as H3 receptor ligands | CEPHALON, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| WO-2008013838-A2 | PYRIDIZINONE DERIVATIVES | CEPHALON, INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| WO-2008013838-A2 | PYRIDIZINONE DERIVATIVES | CEPHALON, INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| US-5919793-A | QUINUCLIDINE DERIVATIVES, SQUALENE SYNTHETASE INHIBITORS, ANTICHOLESTEROL AGENTS | ZENECA LIMITED (GB) | 1999-07-06 | — | — | US | disclosed |
| CN-1121718-A | Heterocyclic derivatives | ZENECA LTD (GB) | 1996-05-01 | — | — | CN | disclosed |
| EP-0696284-A1 | HETEROCYCLIC DERIVATIVES | ZENECA LIMITED (GB) | 1996-02-14 | — | — | EP | disclosed |
| WO-1994025459-A1 | HETEROCYCLIC DERIVATIVES | ZENECA LIMITED (GB) | 1994-11-10 | — | — | WO | disclosed |
| EP-0288190-B1 | IMPROVEMENTS IN OR RELATING TO LEUKOTRIENE ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1992-07-08 | — | — | EP | disclosed |
| US-4874777-A | ANTIASTHMATICS | ELI LILLY AND COMPANY (US) | 1989-10-17 | — | — | US | disclosed |
| CN-88101939-A | Improvement to the leukotriene antagonist or the parties concerned | — | 1988-12-14 | — | — | CN | disclosed |
| EP-0288190-A1 | Improvements in or relating to leukotriene antagonists | ELI LILLY AND COMPANY (US) | 1988-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142088-A1 | PYRIDAZINONE DERIVATIVES | HRH3, HNMT, HRH4 | HSD17B3 298/4885CA12 4825/4885CA1 4135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.